Arcutis Biotherapeutics, Inc. (ARQT)

NASDAQ: ARQT · USD

$31.5

-0.23 (-0.7%)· Recorded snapshot

Market cap	4B
Revenue (ttm)	464M
Net income (ttm)	28.5M
EPS (ttm)	$0.22
Shares out	125.7M
P/E (trailing)	146.0x
P/E (forward)	46.5x
Volume	1,375,599
Beta	1.58

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 464M
Net income (ttm): 28.5M
EPS (ttm): $0.22
P/E (trailing): 146.0x
P/E (forward): 46.5x
Market cap: 4B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ถือ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E46.5

P25 n/aP50 n/aP75 n/a

Trailing P/E146

P25 n/aP50 n/aP75 n/a

ROE15.9

P25 n/aP50 n/aP75 n/a

ROIC37.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All ARQT indicators

Market & fundamental data

Available fields

237

Groups with data

Currency

USD

Showing 237 of 237 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001787306
Company name	Arcutis Biotherapeutics, Inc.
Country	United States
Country code	US
CUSIP number	03969K108
Earnings date	2026-11-04
Earnings time	amc
Employees	354
Employees change	12
Employees growth	3.51%
Enterprise value	$3.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2016
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-01-31
Is primary listing	Yes
Is SPAC	No
ISIN number	US03969K1088
Last 10-K release date	2026-02-25
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$4B
Market cap category	Mid-Cap
Next earnings date	2026-11-04
Options	Yes
Price	$31.45
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	ARQT
U.S. state	California
Website	https://www.arcutis.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	149.76x
Earnings yield	0.68%
EV/Earnings	135.26x
EV/EBIT	112.62x
EV/EBITDA	105.68x
EV/FCF	98.53x
EV/Sales	8.31x
FCF / EV yield	1.01%
FCF yield	0.98%
Forward EV/Sales	6.38x
Forward P/E	46.48x
Forward P/S	6.58x
Graham number	2.91764
Graham upside	-90.79%
P/B ratio	18.04x
P/E ratio	146x
P/FCF ratio	101.71x
P/OCF ratio	101.3x
P/S ratio	8.58x
Price / tangible book value	19.25x
Price/EBITDA ratio	109.08x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	7.38%
EBITDA margin	7.87%
Effective tax rate	2.66%
FCF margin	8.44%
Gross margin	91.14%
Operating margin	7.38%
Pretax margin	6.31%
Profit margin	6.15%
Profit per employee	$80,562
Profitable quarters	1
Revenue per employee	$1.3M
ROA	5.09%
ROA (5Y)	-28.77%
ROCE	10.44%
ROE	15.86%
ROE (5Y)	-98.85%
ROIC	37.79%
SBC / revenue	9.39%
Tax / revenue	0.17%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	13
EPS growth years	3
FCF growth (Q)	4,973.58%
FCF growth (QoQ)	457.44%
Gross profit growth	80.15%
Gross profit growth (Q)	60.68%
Gross profit growth 3Y	256.37%
Net income growth quarters	12
Net income growth years	3
OCF growth (Q)	3,800.93%
OCF growth (QoQ)	464.49%
Revenue growth	76.11%
Revenue growth (Q)	59.33%
Revenue growth (QoQ)	23.21%
Revenue growth 3Y	241.43%
Revenue growth quarters	12
Revenue growth years	3

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-158,000
Depreciation and amortization	$2.3M
EBIT	$34.3M
EBITDA	$36.5M
EPS	$0.22
FCF per share	$0.31
Financing cash flow	$8.3M
Free cash flow	$39.2M
Free cash flow minus SBC	$-4.4M
Gross profit	$422.9M
Income taxes	$779,000
Investing cash flow	$-86M
Net cash flow	$-38.6M
Net income	$28.5M
Operating cash flow minus SBC	$-4.2M
Operating income	$34.3M
Revenue	$464M
Stock-based compensation	$43.5M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	4.86
Book value per share	$1.76
Debt / EBITDA	3.06
Debt / equity	0.52
Debt / FCF	2.92
Interest coverage	2.47
Long-term assets	$20.9M
Long-term liabilities	$107.6M
Net cash (debt)	$124.4M
Net cash / market cap	3.12%
Net cash growth	54.25%
Net debt / EBITDA	-3.41
Net debt / equity	-0.56
Net debt / FCF	-3.18
Piotroski F-Score	7
Property, plant and equipment	$5.1M
Shareholders' equity	$220.6M
Tangible book value	$206.9M
Tangible book value per share	$1.65
Total assets	$488.5M
Total cash	$238.6M
Total debt	$114.1M
Total liabilities	$268M
WACC	12.91%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	1.1
Current assets	$467.7M
Current liabilities	$160.3M
Current ratio	2.92
Inventory turnover	1.49
Net working capital	$75.7M
Quick ratio	2.46
Working capital	$307.3M
Working capital turnover	1.73

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-5.07%
Dividend yield	0%
Shareholder yield	-5.07%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$25.15
1D price change	-0.73%
1M price change	16.79%
1M total return	16.79%
1W price change	-4.2%
1W total return	-4.2%
1Y price change	60.08%
1Y return CAGR	60.13%
1Y total return	60.08%
20-day SMA	$28.32
200-day SMA	$25.19
3M price change	12.93%
3M total return	12.93%
3Y price change	1,246.47%
3Y return CAGR	137.86%
3Y total return	1,246.47%
50-day SMA	$26.42
50-day SMA vs 200-day SMA	50over200
52-week high	$33.30
52-week high date	2026-10-20
52-week low	$19.30
52-week low date	2026-05-19
5Y price change	48.93%
5Y return CAGR	8.29%
5Y total return	48.93%
6M price change	34.24%
6M total return	34.24%
After-hours change	0%
After-hours close	$31.45
After-hours price	$31.45
All-time high	$40.88
All-time high date	2020-03-20
All-time low	$1.76
All-time low date	2023-12-01
Average true range (ATR)	$1.36
Average volume	2.3M
Beta (1Y)	0.48
Beta (2Y)	0.7
Beta (5Y)	1.58
Change from 52-week high	-5.56%
Change from 52-week low	63%
Change from all-time high	-23.09%
Change from all-time low	1,686.36%
Change from open	-0.98%
Day's gap	0.25%
Dollar volume	$43.3M
High price	$31.92
Low price	$31.41
Monthly RSI	65.6
Open price	$31.76
Position in 52-week range	7.84%
Premarket change	0.06%
Premarket close	$31.68
Premarket price	$31.70
Premarket volume	3K
Previous close	$31.68
Price vs 150-day SMA	25%
Price vs 20-day SMA	11.03%
Price vs 200-day SMA	24.81%
Price vs 50-day SMA	19.01%
Relative volume	0.6
Return from IPO open	37.44%
Return from IPO price	86.35%
RSI	64.14
Sharpe ratio	1.02
Sharpe ratio (3Y)	1.49
Sharpe ratio (5Y)	0.4
Sortino ratio	1.89
Sortino ratio (3Y)	2.69
Sortino ratio (5Y)	0.7
Volume	1.4M
Weekly RSI	66.77
YTD price change	8.26%
YTD total return	8.26%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	93.8M
Float percentage	74.64%
Shares change (QoQ)	5.05%
Shares change (YoY)	5.07%
Shares held by insiders	1.03%
Shares held by institutions	88.92%
Shares outstanding	125.7M
Short % of float	23.12%
Short % of shares	17.26%
Short ratio	6.5 days

Deeper analysis on ARQT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this ARQT report

Is a complete ARQT research report available?

No complete published report is available for Arcutis Biotherapeutics, Inc. (ARQT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Arcutis Biotherapeutics, Inc. (ARQT)

Price

Financial snapshot

Fair-value bridge

Latest news · ARQT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All ARQT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on ARQT

Frequently asked questions